Skip to main content
SpringerLink
Log in

Prostate-Specific Antigen and Detecting Early Prostate Cancer: The Importance of Race and Patient Age

  • Chapter
Epidemiology of Prostate Disease

Abstract

Although discovered more than 20 years ago, prostate-specific antigen (PSA) did not receive clinical attention until 1986. Since then, however, it has been the center of intense investigation at both the basic science and clinical levels. As a result, much has been learned about this glycoprotein, and today it must be considered the most useful tumor marker available for the diagnosis and management of prostate cancer (Oesterling 1991). It is superior not only to prostatic acid phosphatase but also to digital rectal examination (DRE).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH (1992) The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147:817–821

    PubMed  CAS  Google Scholar 

  • Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479

    PubMed  CAS  Google Scholar 

  • Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH (1992) Screening for prostatic carcinoma with prostate-specific antigen. J Urol 147:841–845

    PubMed  CAS  Google Scholar 

  • Brendler CB, Carmichael M, Walsh PC, Epstein JI (1993) Radical prostatectomy (RP) for nonpalpable prostate cancer diagnosed by needle biopsy: pathologic and clinical findings. J Urol 149:378A

    Google Scholar 

  • Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215–2220

    Article  PubMed  CAS  Google Scholar 

  • Catalona WJ, Bigg SW (1990) Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 143:538–543

    PubMed  CAS  Google Scholar 

  • Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Copien DE, Yuan JJJ, Petros JA, Andriole GL (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161

    Article  PubMed  CAS  Google Scholar 

  • Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA 270:948–954

    Article  PubMed  CAS  Google Scholar 

  • Collins GN, Lee RJ, McKelvie GB, Rogers ACN, Hehir M (1993) Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 71:445–450

    Article  PubMed  CAS  Google Scholar 

  • Cooner WH (1993) Early diagnosis of prostate cancer. In: Campbell’s urology, 6th edn. Saunders, Philadelphia, Update 4:1–10

    Google Scholar 

  • Crawford ED (1993) Report on the 1992 prostate cancer awareness week. J Urol 149:55A

    Google Scholar 

  • Dalkin BL, Ahmann FR, Kopp JB (1993a) Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150:1837–1839

    PubMed  CAS  Google Scholar 

  • Dalkin BL, Ahmann F, Southwick P, Bottaccini MR (1993b) Derivation of normal prostate specific antigen (PSA) level by age. J Urol 149:413A

    Google Scholar 

  • Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE (1993) A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269:2650–2658

    Article  PubMed  CAS  Google Scholar 

  • Gerber GS, Thompson IM, Thisted R, Chodak GW (1993) Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 269:61–64

    Article  PubMed  CAS  Google Scholar 

  • Jewett HJ, Bridge RW, Gray GF Jr, Shelley WM (1968) The palpable nodule of prostate cancer: results 15 years after radical excision. JAMA 203:403–406

    Article  PubMed  CAS  Google Scholar 

  • Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA (1989) Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 141:1091–1094

    PubMed  CAS  Google Scholar 

  • Klee GG, Dodge LA, Zincke H, Oesterling JE (1994) Measurement of serum prostate specific antigen concentration using IMx prostate specific antigen assay. J Urol 151:94–98

    PubMed  CAS  Google Scholar 

  • Lilja H, Christensson A, Dahlen V, Matikainen MT, Nilsson O, Pettersson K, Lovgen T (1991) Prostate-specific antigen in human serum occurs predominately in complex with alpha-1-antichymotrypsin. Clin Chem 37:1618–1625

    PubMed  CAS  Google Scholar 

  • Lu-Yao GL, McLerran D, Wasson J, Wennberg JE (1993) An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA 269:2633–2636

    Article  PubMed  CAS  Google Scholar 

  • Oesterling JE (1991) Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923

    PubMed  CAS  Google Scholar 

  • Oesterling JE, Bilhartz DL, Tindall DJ (1991) Clinically useful serum markers for adenocarcinoma of the prostate. II. Prostate-specific antigen. Am Urol Assoc Update Ser 10:137–144

    Google Scholar 

  • Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993a) Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860–864

    Article  PubMed  CAS  Google Scholar 

  • Oesterling JE, Suman VJ, Bostwick DG, Zincke H (1993b) PSA-detected (clinical stage Tlc or Bo) prostate cancer: pathologically significant tumors. Urol Clin North Am 20:687–693

    PubMed  CAS  Google Scholar 

  • Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, Jacobsen SJ, Lieber MM (1995) Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged Caucasians. Br J Urol 75:347–353

    Article  PubMed  CAS  Google Scholar 

  • Scaletscky R, Koch MO, Eckstein CW, Smith JA Jr (1993) Pathologic findings in prostate cancer detected because of PSA elevation. J Urol 149:303A

    Google Scholar 

  • Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz M, Pavone-Macaluso M (1992) The TNM classification of prostate cancer. Prostate [Suppl] 4:129–138

    Article  Google Scholar 

  • Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specific antigen and alphal-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222–226

    PubMed  CAS  Google Scholar 

  • Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, Oesterling JE (1993) Clinical stage Bo or Tlc prostate cancer: nonpalpable prostate cancer identified by an elevated serum prostate-specific antigen concentration. Urology 41:3–8

    Article  PubMed  CAS  Google Scholar 

  • Thompson IM, Rounder JB, Teague JL, Peek M, Spence CR (1987) Impact of routine screening for adenocarcinoma of the prostate on stage distribution. J Urol 137:424–426

    PubMed  CAS  Google Scholar 

  • Vessella RL, Noteboom J, Lange PH (1992) Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. Clin Chem 38:2044–2054

    PubMed  CAS  Google Scholar 

  • Whitmore WF Jr (1993) Management of clinically localized prostate cancer: an unresolved problem. JAMA 269:2676–2677

    Article  PubMed  Google Scholar 

Download references

Authors
  1. J. E. Oesterling
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Public Health Sciences, University of Edinburgh Medical School, Teviot Place, Edinburgh, EH8 9AG, UK

    Michael Garraway

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Oesterling, J.E. (1995). Prostate-Specific Antigen and Detecting Early Prostate Cancer: The Importance of Race and Patient Age. In: Garraway, M. (eds) Epidemiology of Prostate Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78826-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78826-0_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78828-4

  • Online ISBN: 978-3-642-78826-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation